NCT06649851View on ClinicalTrials.gov

G-CSF After Chemo-radiation in Patients With Glioblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2030

Conditions
MGMT-Methylated GlioblastomaGlioblastoma (GBM)Newly Diagnosed Glioblastoma Multiforme
Interventions
DRUG

Granulocyte Colony Stimulating Factor (G-CSF)

Subcutaneously injected study drug; standard target dose of 5-7 µg/kg/d.

RADIATION

Radiation Therapy + Temozolomide

Standard of care chemoradiation is radiation therapy + Temozolomide (TMZ). Chemoradiation (chemo-RT) includes an initial 6-week cycle, followed by a 4-week break, and up to 6 additional cycles of TMZ.

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER